General Electric said that Bill Castell, CEO of GE Healthcare, will retire next year. He will be replaced by Joe Hogan upon his retirement. The appointment was included in an announcement about the realigning of GE's businesses.
Thomas McLain has been appointed to the board of directors of the Biotechnology Industry Organization, effective June 21, 2005. McLain is one of 11 new board members, who will each serve two-year terms.
McLain is currently the chairman, CEO and president of Nabi Pharmaceuticals. Prior to joining Nabi Pharmaceuticals in 1998, McLain was employed by Bausch & Lomb.
Guava Technologies last week launched four new assays for its microplate-based EasyCyte benchtop microcytometry system.
The four new cellular assays are for assessing mitochondrial membrane potential, cellular proliferation, and activation of caspase 3/7 or 8 enzymes.
The Guava MitoPotential Assay measures changes in the ion gradient across the mitochondrial membrane. The Caspase 3/7 and Caspase 8 Assays detect the initial or middle stages of programmed cell death. The CellGrowth Assay provides measurements of cellular division out to several generations, Guava said.
Research and Markets has released a Survey of Current Applications of Fluorescent Proteins in Drug Discovery, the Dublin, Ireland-based market research firm said last week.
The survey is based on the responses of 519 pharmaceutical scientists and managers who completed a questionnaire between April 7 and May 7, 2004, Research and Markets said.
According to the survey, 89 percent of those questioned said that the availability of GFP had improved lead discovery productivity.
For more information on the survey, interested parties can go to http://www.researchandmarkets.com/reports/c19841.